You just read:

Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-β-Cyclodextrin (2HPβCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)

News provided by

Variant Pharmaceuticals, Inc.

Oct 24, 2018, 13:08 ET